Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: Clarus, Agile and Sunovion Look To Bounce Back From CRLs; FDA To Review Rituximab Biosimilar

Jul 02 2017

• By Michael Cipriano

Keeping Track Feature image

Related Content

Clarus’ Oral Testosterone’s Perceived Advantage Becomes Downfall At FDA Panel

Sep 19 2014

Keeping Track: Neurology And Breakthroughs Stay In Spotlight As US FDA Approves Radicava, Imfinzi; TaiMed Submits Ibalizumab

May 06 2017

Keeping Track: Gazyva, Afinitor Get New Indications; PTC's Translarna Gets Refuse To File

Feb 29 2016

Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar

Apr 24 2017

Keeping Track: Novartis, Calardius Pick Up Speed; ADMA Stumbles

Aug 05 2016

Keeping Track: FDA Nixes Medicure’s Aggrastat For STEMI, Approves Insys’ Syndros

Jul 10 2016

Subcutaneous Rituximab Seems Headed For US FDA Advisory Panel OK

Mar 28 2017

Agile's Phase III Data For Twirla Patch Fall Flat, Raise Doubts On Approval

Jan 05 2017

Keeping Track: Oncology Announcements, Priority Review Vouchers Continue To Pile Up

Jun 05 2017

Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates

Oct 06 2016

Agile SEC filing reveals FDA rejection for Twirla contraceptive

Mar 19 2014

Additional Topics

United States Drug Review Approvals Drug Approval Standards Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window